机构:[1]CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China[2]Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People’s Hospital, Shenzhen 518112, China[3]CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China[4]University of the Chinese Academy of Sciences, Beijing 100049, China[5]Laboratory of Protein Engineering and Vaccines, Tianjin Institute of Biotechnology, Tianjin 300308, China[6]College of Animal Science and Veterinary Medicine, Shanxi Agricultural University, Taigu 030801, China[7]Institute of Physical Science and Information, Anhui University, Hefei 230039, China[8]West China Hospital Emergency Department (WCHED), State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan 610041, China四川大学华西医院[9]School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230026, China[10]State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region 999077, China[11]Department of Microbiology, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region 999077, China[12]Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai 201204, China[13]College of Life Science, University of the Chinese Academy of Sciences, Beijing 100049, China[14]Savaid Medical School, University of the Chinese Academy of Sciences, Beijing 100049, China
This work was supported
by the Strategic Priority Research Program of CAS (XDB29010202 and XDB29040302), the National Key Research and Development Program of
China (2016YFD0500305), the National Natural Science Foundation of China
(81922044, 81673358 and 81973228), and the Zhejiang University Special Scientific
Research Fund for COVID-19 Prevention and Control (2020XGZX031).
Q.W. is supported by Youth Innovation Promotion Association CAS grant
2018119. G.L. is supported by the special research fund on COVID-19 of Sichuan
Province (2020YFS0010) and the special research fund on COVID-19
of West China Hospital Sichuan University (HX-2019-nCoV-004). J.Y is supported
by Foundation of the NSFC Innovative Research Group grant
81621091.
第一作者机构:[1]CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China[2]Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People’s Hospital, Shenzhen 518112, China[3]CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
共同第一作者:
通讯作者:
通讯机构:[1]CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China[2]Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People’s Hospital, Shenzhen 518112, China[3]CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China[7]Institute of Physical Science and Information, Anhui University, Hefei 230039, China[13]College of Life Science, University of the Chinese Academy of Sciences, Beijing 100049, China[14]Savaid Medical School, University of the Chinese Academy of Sciences, Beijing 100049, China
推荐引用方式(GB/T 7714):
Qihui Wang,Yanfang Zhang,Lili Wu,et al.Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.[J].CELL.2020,181(4):894-+.doi:10.1016/j.cell.2020.03.045.
APA:
Qihui Wang,Yanfang Zhang,Lili Wu,Sheng Niu,Chunli Song...&Jianxun Qi.(2020).Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2..CELL,181,(4)
MLA:
Qihui Wang,et al."Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.".CELL 181..4(2020):894-+